Inhibition of Cyclooxygenase-2 Gene Expression by p53*

Oncogenes enhance the expression of cyclooxygenase (Cox)-2, but interactions between tumor suppressor genes and Cox-2 have not been studied. In the present work, we have compared the levels of Cox-2 and the production of prostaglandin E2 in mouse embryo fibroblasts that do not express any p53 ((10)1) versus the same cell line ((10.1)Val5) engineered to overexpress wild-type (wt) p53 at 32 °C or mutant p53 at 39 °C. Cells expressing wt p53 showed about a 10-fold decrease in synthesis of prostaglandin E2 compared with those expressing mutant p53. Levels of Cox-2 protein and mRNA were markedly suppressed by wt p53 but not by mutant p53. Nuclear run-offs revealed decreased rates of Cox-2 transcription in cells expressing wt p53. The activity of the Cox-2 promoter was reduced by 85% in cells expressing wt p53 but was reduced only by 30% in cells expressing mutant p53 compared with cells null for p53. The effect of p53 on the suppression of Cox-2 promoter activity was localized to the first 40 base pairs 5′ from the transcription start site. Electrophoretic mobility shift assay revealed that p53 competed with TATA-binding protein for binding to mouseCox-2 or human Cox-2 promoter extending from −50 to +52 base pairs. The results of this study suggest that interactions between p53 and Cox-2 could be important for understanding why levels of Cox-2 are undetectable in normal cells and increased in many tumors.

[1]  L. Ellis,et al.  Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. , 1998, Cancer research.

[2]  R. DuBois,et al.  Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.

[3]  Li Zhu,et al.  Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. , 1998, Cancer research.

[4]  K. Seibert,et al.  Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. , 1998, Cancer research.

[5]  Fan Zhang,et al.  Dihydroxy Bile Acids Activate the Transcription of Cyclooxygenase-2* , 1998, The Journal of Biological Chemistry.

[6]  K. Kinzler,et al.  Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Morrow,et al.  Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. , 1998, Cancer research.

[8]  J. Morrow,et al.  A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. , 1997, Gastroenterology.

[9]  K. Subbaramaiah,et al.  Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. , 1997, Cancer research.

[10]  R. DuBois,et al.  Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  K. Subbaramaiah,et al.  Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. , 1997, Carcinogenesis.

[12]  A. Ristimäki,et al.  Expression of cyclooxygenase-2 in human gastric carcinoma. , 1997, Cancer research.

[13]  F. Robertson,et al.  Cyclooxygenase-2 gene expression in human breast cancer. , 1997, International journal of oncology.

[14]  William L. Smith,et al.  Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and −2* , 1996, The Journal of Biological Chemistry.

[15]  Y. Hannun Functions of Ceramide in Coordinating Cellular Responses to Stress , 1996, Science.

[16]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[17]  K. Subbaramaiah,et al.  Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. , 1996, Cancer research.

[18]  H. Werner,et al.  Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  B. A. Ballif,et al.  Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. White,et al.  Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[22]  H. Herschman Prostaglandin synthase 2. , 1996, Biochimica et biophysica acta.

[23]  R. DuBois,et al.  Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 , 1995, Cell.

[24]  C. Yokoyama,et al.  Transcriptional Regulation of Human Prostaglandin-endoperoxide Synthase-2 Gene by Lipopolysaccharide and Phorbol Ester in Vascular Endothelial Cells , 1995, The Journal of Biological Chemistry.

[25]  M. Kondo,et al.  Expression of cyclooxygenase-1 and -2 in human colorectal cancer. , 1995, Cancer research.

[26]  G. Stark,et al.  p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S Jothy,et al.  Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. , 1995, Cancer research.

[28]  D. Pinkel,et al.  Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. , 1995, Genes & development.

[29]  F. Marks,et al.  Differential expression of prostaglandin h synthase isozymes during multistage carcinogenesis in mouse epidermis , 1995, Molecular carcinogenesis.

[30]  T. Shenk,et al.  Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Maclouf,et al.  Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[32]  S. Deb,et al.  Wild-type human p53 activates the human epidermal growth factor receptor promoter. , 1994, Oncogene.

[33]  J. Morrow,et al.  Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. , 1994, The Journal of clinical investigation.

[34]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[35]  J. Pipas,et al.  Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53 , 1993, Nature.

[36]  V. Rotter,et al.  Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. , 1993, Oncogene.

[37]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[38]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[39]  David A Jones,et al.  Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. , 1993, The Journal of biological chemistry.

[40]  M. Oren,et al.  mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.

[41]  G. Zambetti,et al.  Wild-type p53 binds to the TATA-binding protein and represses transcription. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[42]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[43]  A. Levine,et al.  p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. , 1991, Genes & development.

[44]  U. Santhanam,et al.  Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[45]  B. Varnum,et al.  TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. , 1991, The Journal of biological chemistry.

[46]  B. Vogelstein,et al.  p53 functions as a cell cycle control protein in osteosarcomas , 1990, Molecular and cellular biology.

[47]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[48]  M. Oren,et al.  Wild-type p53 can inhibit oncogene-mediated focus formation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[49]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[50]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[51]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.